Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Клинический случай эффективного лечения лапатинибом (Тайверб) и капецитабином (Кселода) больной диссеминированным раком молочной железы с гиперэкспрессией ErbB2 (Her-2/neu) с метастатическим поражением вещества и оболочек головного мозга
Клинический случай эффективного лечения лапатинибом (Тайверб) и капецитабином (Кселода) больной диссеминированным раком молочной железы с гиперэкспрессией ErbB2 (Her-2/neu) с метастатическим поражением вещества и оболочек головного мозга
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Chang E, Lob S. Diagnosis and Management of Central Nervous System Metastases from Breast Cancer. The Oncologist 2003; 8 (5): 398–410.
2. Bendell JC, Domchek SM, Burstein HJ et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003; 97: 2972–7.
3. Burstein HJ, Lieberman G, Slamon DJ et al. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol 2005; 16: 1772–7.
4. De la Monte SM, Hutchins GM, Moore GW. Estrogen and progesterone receptors in prediction of metastatic behavior of breast carcinoma. Am J Med 1984; 76: 11–7.
5. Heinrich B, Brudler O, Siekiera W et al. Development of brain metastasis in metastatic breast cancer responding to treatment with trastuzumab. Proc Am Soc Clin Oncol 2003; 22: 37 (abstr 147).
6. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004; 22: 3608–17.
7. Wardley AM, Danson S, Clayton AJ et al. High incidence of brain metastases in patients treated with trastuzumab for metastatic breast cancer at a large cancer center. Proc Am Soc Clin Oncol 2002; 21: 61a (abstr 241).
8. Samaan NA, Buzdar AU, Aldinger KA et al. Estrogen receptor: A prognostic factor in breast cancer. Cancer 1981; 47: 554–60.
9. Weitzen R, Zach L, Kaufman B et al. High incidence of brain metastasis in patients on trastuzumab for advanced breast cancer. Proc Am Soc Clin Oncol 2002; 21: 316 (abstr 1936).
10. Bezjak A, Adam J, Barton R et al. Symptom response after palliative radiotherapy for patients with brain metastases. Eur J Cancer 2002; 38: 487–96.
11. Khuntia D, Brown P, Li J et al. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol 2006; 24: 1295–304.
12. Tsao MN, Lloyd N, Wong R et al. Whole brain radiotherapy for the treatment of multiple brain metastases. Cochrane Database Syst Rev 2006; 3: CD003869.
13. Fabi A, Vidiri A, Ferretti G et al. Dramatic regression of multiple brain metastases from breast cancer with capecitabine: Another arrow at the bow? Cancer Invest 2006; 24: 466–8.
14. Hikino H, Yamada T, Johbara K et al. Potential role of chemo-radiation with oral capecitabine in a breast cancer patient with central nervous system relapse. Breast 2006; 15: 97–9.
15. Siegelmann-Danieli N, Stein M, Bar-Ziv J. Complete response of brain metastases originating in breast cancer to capecitabine therapy. Isr Med Assoc J 2003; 5: 833–4.
16. Wang ML, Yung WK, Royce ME et al. Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer. Am J Clin Oncol 2001; 24: 421–4.
17. Lin NU, Carey LA, Liu MC et al. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. J Clin Oncol 2006; 24 (suppl. 18): 503a.
2. Bendell JC, Domchek SM, Burstein HJ et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003; 97: 2972–7.
3. Burstein HJ, Lieberman G, Slamon DJ et al. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol 2005; 16: 1772–7.
4. De la Monte SM, Hutchins GM, Moore GW. Estrogen and progesterone receptors in prediction of metastatic behavior of breast carcinoma. Am J Med 1984; 76: 11–7.
5. Heinrich B, Brudler O, Siekiera W et al. Development of brain metastasis in metastatic breast cancer responding to treatment with trastuzumab. Proc Am Soc Clin Oncol 2003; 22: 37 (abstr 147).
6. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004; 22: 3608–17.
7. Wardley AM, Danson S, Clayton AJ et al. High incidence of brain metastases in patients treated with trastuzumab for metastatic breast cancer at a large cancer center. Proc Am Soc Clin Oncol 2002; 21: 61a (abstr 241).
8. Samaan NA, Buzdar AU, Aldinger KA et al. Estrogen receptor: A prognostic factor in breast cancer. Cancer 1981; 47: 554–60.
9. Weitzen R, Zach L, Kaufman B et al. High incidence of brain metastasis in patients on trastuzumab for advanced breast cancer. Proc Am Soc Clin Oncol 2002; 21: 316 (abstr 1936).
10. Bezjak A, Adam J, Barton R et al. Symptom response after palliative radiotherapy for patients with brain metastases. Eur J Cancer 2002; 38: 487–96.
11. Khuntia D, Brown P, Li J et al. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol 2006; 24: 1295–304.
12. Tsao MN, Lloyd N, Wong R et al. Whole brain radiotherapy for the treatment of multiple brain metastases. Cochrane Database Syst Rev 2006; 3: CD003869.
13. Fabi A, Vidiri A, Ferretti G et al. Dramatic regression of multiple brain metastases from breast cancer with capecitabine: Another arrow at the bow? Cancer Invest 2006; 24: 466–8.
14. Hikino H, Yamada T, Johbara K et al. Potential role of chemo-radiation with oral capecitabine in a breast cancer patient with central nervous system relapse. Breast 2006; 15: 97–9.
15. Siegelmann-Danieli N, Stein M, Bar-Ziv J. Complete response of brain metastases originating in breast cancer to capecitabine therapy. Isr Med Assoc J 2003; 5: 833–4.
16. Wang ML, Yung WK, Royce ME et al. Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer. Am J Clin Oncol 2001; 24: 421–4.
17. Lin NU, Carey LA, Liu MC et al. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. J Clin Oncol 2006; 24 (suppl. 18): 503a.
Авторы
Д.Р.Насхлеташвили, Г.Е.Чмутин
ГУ РОНЦ им. Н.Н.Блохина РАМН, Москва
ГУ РОНЦ им. Н.Н.Блохина РАМН, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.